Alpha Spread alternative: guardrails
Alpha Spread ships an Investment Journal on every tier including free, from $12 a month. Here is where that overlaps a monitored thesis and where it does not.
By Javier SanzPublished
Founder of ValueScreener. Built and sold Ninety Nine, a securities services provider, and ran operations and internationalization at Alpaca, the brokerage API.
Who writes thisLinkedIn (opens in a new tab)X (opens in a new tab)
Of everything on this list, Alpha Spread is the closest in shape to what ValueScreener does, and it is worth saying so before anything else. Their plan comparison table, read 2026-09-18, carries an Investment Journal row on all three tiers including the free one, with watchlist alerts and price alerts on all three as well. Writing down your reasoning next to a company, and being told when something moves, is the same instinct this product is built around. They give the first half of it away.
What both do
Both value a business rather than chart it. Both put an intrinsic-value model in front of you with assumptions you can move. Both keep a place to write what you think about a company. Both let you screen. The overlap here is real and this page is not going to minimise it.
The difference that decides it
The difference is what the alert is made of.
On their pricing page as read on 2026-09-18, the published alert rows are Watchlist Alerts and Price Alerts and Reminders, each ticked on all three tiers, with Stock Screener Alerts ticked on the Unlimited tier only. Their own tooltip for the price alerts reads: "Ensure you never miss out on a buying or selling point with our tailored price alerts. Customize your alerts and let Alpha Spread watch the market for you." That is the market being watched. The tooltip for the screener alerts is the closest of the three to a rule on a number: "You can set up alerts based on your custom stock screener criteria. Each week, we'll send you an email update with new stocks that match your specified filters." That is a weekly digest of companies entering a screen. Whether a user can set a numeric condition on one company's accounts and be emailed when a newly filed statement breaks it is not stated on that page, so we record it as not established rather than as absent.
A guardrail here is the other thing. It is a numeric rule you attach to a written thesis, stated in the vocabulary of the accounts: a margin that must not fall under a level, a coverage ratio that must stay above one, a streak that must not break. Every night, after the newest filings are ingested, each rule is recomputed from the filed statements and tested again. When one breaks, one email goes out, once, with the arithmetic attached and the filing it came from. When nothing breaks, nothing arrives. The per-thesis record of each night's pass is in the product, so a quiet week is checkable rather than assumed.
The second difference is provenance. Their DCF pages publish a View Calculation control, so the model's arithmetic is openable, which is a real piece of showing your work. What we could not find published on their own site as of 2026-09-18 is a trace from a displayed figure back to the source statement, the fiscal year and the filing date. Absence of published evidence, again, and not a denial.
The third is the screener, and it runs the other way on price. Their plan table marks Stock Screener with a cross on Free and on Premium and a check on Unlimited only. Screening here is in the one tier, because there is only one tier.
What each costs
| Alpha Spread, as published | ValueScreener | |
|---|---|---|
| Free tier | "$0/mo", 3 stocks per week | None |
| Entry paid tier | "$12/mo", "Billed annually at $144" | $228/year, or $29/month |
| Top tier | "$20/mo", "Billed annually at $240" | Same one tier |
| Business | Enterprise, "From $150/mo", with an API | Not offered |
| Trial | No trial published; the free plan is the entry | 14 days, card required, first charge on day 15 |
| Refund | "a 14-day money-back guarantee for new customers" | 30 days from your first payment |
Their figures are quoted from their own service pricing page as read on 2026-09-18. Note the URL: their pricing lives at /service-pricing, and /pricing answered 404 in a browser on the same day. A 30% discount for students and teachers is published on the same page.
Where Alpha Spread is better
The Investment Journal is on the free tier. That is the single strongest thing on this page and it should not be written around: note-taking against a company costs nothing there, and it costs $29 a month here.
Their reverse DCF stress-tests one driver at a time, which answers the question a forward DCF cannot: what would have to be true for today's price to be right. This product ships a two-stage forward DCF and no reverse model.
Their Valuation Backtest asks whether the intrinsic-value estimate would have been right historically, which most valuation tools do not attempt at all. It is metered at 15 a week on Premium and unlimited on their top tier. There is no equivalent here.
They cover far more of the world. Their own search box reads "Search 100,000+ stocks", and one company page lists the cross-listings under an "Other listings" heading: on Apple's DCF page, read 2026-09-18, ten of them, from the LSE and XETRA to the Bolsa Mexicana de Valores. That matters if you want to compare a US line against its European one. This product covers NYSE, NASDAQ and AMEX and nothing else.
They are cheaper at every point of comparison: $144 a year against $228, with a usable free tier at three reports a week and a published student discount. There is an Enterprise tier from $150 a month with an API, and the site ships in English, German and Spanish. None of those exist here.
Who should pick which
If you want a valuation platform with a wide universe, a stress-testable model, somewhere to keep notes, and the lowest price on this page, theirs does that and the free tier lets you find out for nothing.
If the thing you actually want is for a number you chose to be re-tested against newly filed accounts every night, and for an email to arrive on the day it breaks and on no other day, that is the specific job ValueScreener was built for. Both are research tools, neither gives advice, and this page is a comparison of software and not a view on any company.
What this leaves out
Every claim about Alpha Spread here was read on their own service pricing page on 2026-09-18, with three observations taken from a signed-out DCF valuation page on the same day. Their plan table marks capabilities with an icon rather than a word, so the ticks and crosses quoted here were read out of the table's own markup and not inferred from the rendered text. We did not sign in, so anything only visible inside an account is not described. Where this page says a capability was not found, that is absence of published evidence on the pages read, not a statement that it does not exist.